Kanabo Group establishes EU-GMP production line for its Hemp CBD line

Francesca Morgan
Vox Newswire
10:32, 25th June 2021

Kanabo Group (KNB FOLLOW) said it has established a EU-GMP production line for the group’s medical grade Hemp CBD line in partnership with CBD manufacturer Pure Origin Group. 

Pure Origin Group had originally created a dedicated production line for Kanabo's CBD Wellness formulas using Kanabo's equipment, production protocols and IP in May 2021.  

Kanabo, which distributes cannabis-derived products, said it chose Pure Origin Group for its Good Manufacturing Practices (GMPs) to regulate production, verification and validation, ensuring that its finished products are ‘effective and safe for market distribution.’ 

Kanabo said that this production line marks the end of its pilot sales and preludes a full product launch within its primary markets. As a result, the group said it will now embark on the second phase of its sales plan to increase revenue from the sale of CBD products. 

Shares in Kanabo Group were trading 0.53% higher this morning to 19p following the news. 

KNB price chart

The pilot sales, which has lasted a period of three months, has provided several important performance measures in relation to the sale of Kanabo's retail CBD products in the UK.   

"In one month we have succeeded in a joint effort with the Pure Origin team to establish a EU-GMP production line for Kanabo's medical grade Hemp CBD line. This production is a key achievement that will bring a new quality of medical CBD vape products that were not previously available on to the UK market,” said Kanabo’s Chief Executive, Avihu Tamir. 

Pure Origin’s Joint MD, Tony Rolfe, said, "We are delighted to partner with Kanabo in the run up to full production and product launch of their EU-GMP manufactured CBD formulas." 

Follow News & Updates from Kanabo Group here: FOLLOW

 

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist